Immune Systems Advisor

Ebola Virus Disease (EVD) is a severe, often fatal illness in humans. Historically managed purely through supportive care, the landscape of Ebola virus disease therapeutics has shifted dramatically. Thanks to landmark clinical trials, clinicians now deploy highly targeted, FDA-approved therapies that significantly reduce mortality rates. The Evolution of Ebola Therapeutics: The PALM Trial Benchmark The turning point for modern Ebola virus disease therapeutics occurred during the 2018–2020 outbreak in the Democratic Republic of the Congo. The Pamoja Tulinde Maisha (PALM) randomized controlled trial, published in The New England Journal of Medicine and indexed on PubMed, revolutionized treatment protocols. The PALM trial evaluated four distinct therapeutic candidates. It conclusively demonstrated that targeted monoclonal antibodies offered a vastly superior survival advantage compared to standard care and early antiviral small molecules. FDA-Approved Monoclonal Antibodies for...

Summary The 2026 Ebola outbreak — driven by the rare Bundibugyo strain — is the most serious in years. With over 900 suspected cases, spread into Uganda, an American infected, and both WHO and aid groups warning that response is lagging behind transmission, the situation is escalating rapidly. International measures now include U.S. travel bans, a Kenya quarantine facility, Uganda's border closure, and an emergency vaccine push. Authorities are bracing for a containment effort lasting through the end of 2026. Updated: May 29, 2026 — A fast-moving Bundibugyo Ebola outbreak in the Democratic Republic of Congo (DRC) and Uganda has triggered urgent international action. Over 1,000 suspected cases reported. WHO has declared a Public Health Emergency of International Concern (PHEIC). The United States is establishing an Ebola quarantine facility in Kenya, and Uganda has closed its border with Congo. What Is the Current Ebola Strain and Where Did It Start? The outbreak is caused by th...

What Is Ensitrelvir and Why Is It Making Headlines in 2026? A new oral antiviral is changing the conversation around COVID-19 prevention. Ensitelvir (brand name Xocova in Japan and Singapore) is the first oral 3CL protease inhibitor shown in a large Phase 3 trial to prevent symptomatic COVID-19 after exposure. Published in the New England Journal of Medicine on May 13, 2026, the SCORPIO-PEP trial delivered clear results: a 67% reduction in the risk of developing symptomatic, PCR-confirmed COVID-19 by day 10 compared with placebo. This isn’t another vaccine or booster. It’s a direct-acting pill you take for just 5 days after close contact with someone who tested positive — no needles, no waiting weeks for immunity to build. How Ensitrelvir Works: Immediate Antiviral Action vs. Delayed Vaccine Immunity Ensitrelvir targets the SARS-CoV-2 main protease (3CLpro or Mpro) — an enzyme the virus needs to replicate. By inhibiting this conserved protein, the pill stops viral multiplicatio...